Centene Corporation
CNC
$61.39
-3.17%
Centene Corporation is a leading managed care organization specializing in government-sponsored healthcare plans, primarily Medicaid, Medicare, and individual health insurance exchanges. The company is a dominant player in the Medicaid managed care market, serving approximately 20 million members, which provides it with significant scale and a defensive revenue base tied to public healthcare programs. The current investor narrative revolves around the company's recovery from a challenging 2025, marked by significant quarterly losses, and its sensitivity to regulatory updates, as evidenced by recent positive sector sentiment following a favorable Medicare Advantage payment announcement from CMS in April 2026.…
CNC
Centene Corporation
$61.39
Related headlines
CNC 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Centene Corporation's 12-month outlook, with a consensus price target around $79.81 and implied upside of +30.0% versus the current price.
Average Target
$79.81
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$49 - $80
Analyst target range
Analyst coverage appears limited with only 5 analysts providing estimates, and the institutional ratings data shows a consensus leaning neutral, with recent actions from firms like JP Morgan, Mizuho, and Morgan Stanley all maintaining 'Neutral' or 'Equal Weight' stances. The estimated EPS range for the forward period is $8.93 to $9.50, with an average of $9.21, indicating analysts expect a strong recovery in profitability, but the lack of a published average target price in the data suggests insufficient consensus to calculate a clear upside or downside signal, which is typical for a stock undergoing a high-degree of earnings uncertainty and re-rating.
Bulls vs Bears: CNC Investment Factors
The bull case, driven by a powerful technical recovery and extreme valuation discount, currently holds stronger evidence due to the stock's undeniable momentum and deeply depressed sales multiple. However, the bear case presents a formidable counter-argument rooted in a severe and ongoing profitability crisis. The single most important tension in the investment debate is whether the company's strong revenue growth and solid cash flow can translate into a sustainable return to profitability, as priced into the forward P/E of 14.63, or if the Q4 2025 losses signal a deeper, structural issue that the recent rally has overlooked. The resolution of this profitability question will determine if CNC is a deep-value turnaround or a value trap.
Bullish
- Powerful Technical Recovery: The stock has surged 89.23% over the past three months and is trading at 98% of its 52-week high, decisively reversing a prior downtrend. This momentum, with a 10.85% gain in the past month, indicates strong buying pressure and a potential breakout above the $66.55 resistance level.
- Extreme Valuation Discount: The stock trades at a trailing Price-to-Sales ratio of 0.104, which is exceptionally low and near the bottom of its own historical range. This deep discount, coupled with a forward P/E of 14.63, suggests the market has priced in significant distress, creating a potential value opportunity if profitability recovers.
- Strong Revenue Growth Trajectory: Q4 2025 revenue grew 21.86% year-over-year to $49.73 billion, demonstrating the company's ability to grow its top line despite profitability challenges. This growth is supported by a dominant position in the defensive Medicaid market, serving approximately 20 million members.
- Positive Regulatory Catalyst: Recent sector-wide positive sentiment was triggered by a favorable 2027 Medicare Advantage payment announcement from CMS in April 2026. This improves revenue visibility for Centene's Medicare segment, which constitutes about 5% of its membership.
Bearish
- Severe Profitability Crisis: Q4 2025 saw a net loss of $1.1 billion and an operating margin of -3.5%, with gross margin compressing to 15.18% from 16.38% in Q3. The trailing Return on Equity is deeply negative at -33.44%, indicating a fundamental breakdown in earnings generation.
- Analyst Skepticism & Lack of Targets: Analyst consensus leans neutral, with recent actions from major firms like JP Morgan and Morgan Stanley maintaining 'Neutral' or 'Equal Weight' ratings. The lack of a published average price target suggests insufficient confidence to signal clear upside, reflecting high earnings uncertainty.
- Vulnerable at Technical Resistance: Trading at $65.19, the stock is testing major resistance at its 52-week high of $66.55. After a parabolic 89% three-month rally, the risk of near-term consolidation or profit-taking is elevated, especially given its beta of 1.09, which implies higher volatility.
- Earnings Quality Concerns: The disconnect between strong free cash flow ($4.32B TTM) and massive net losses (-$1.1B in Q4) raises questions about earnings quality and sustainability. The forward P/E of 14.63 is only valid if the company delivers on the analyst EPS estimate of $9.21, which is not guaranteed.
CNC Technical Analysis
The stock is in a powerful recovery trend, having surged 89.23% over the past three months and 59.58% over six months, decisively reversing a prior downtrend. With a current price of $65.19, the stock is trading at approximately 98% of its 52-week high of $66.55, indicating it is testing major resistance at the upper bound of its yearly range, which suggests strong momentum but also potential for near-term consolidation or profit-taking. Recent momentum remains robust, with a 10.85% gain over the past month, significantly outperforming the S&P 500's -0.08% return, and this short-term acceleration aligns with and reinforces the powerful multi-month uptrend, signaling sustained buying pressure. Key technical levels are the 52-week high at $66.55 acting as immediate resistance and the 52-week low at $25.08 providing distant support; a confirmed breakout above $66.55 could open the path for further gains, while the stock's beta of 1.09 indicates its volatility is moderately higher than the broader market, which is consistent with the magnitude of its recent price swings.
Beta
1.09
1.09x market volatility
Max Drawdown
-59.9%
Largest decline past year
52-Week Range
$25-$67
Price range past year
Annual Return
+12.3%
Cumulative gain past year
| Period | CNC Return | S&P 500 |
|---|---|---|
| 1m | +5.4% | +1.5% |
| 3m | +69.8% | +13.4% |
| 6m | +56.5% | +10.9% |
| 1y | +12.3% | +24.5% |
| ytd | +46.9% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CNC Fundamental Analysis
Revenue growth remains strong, with Q4 2025 revenue of $49.73 billion representing a 21.86% year-over-year increase, though this growth is overshadowed by severe profitability issues in the same quarter. The company's profitability is under significant pressure, as evidenced by a Q4 2025 net loss of $1.1 billion and a gross margin of 15.18%, which compressed from 16.38% in Q3; the operating margin was deeply negative at -3.5%, indicating underlying cost challenges despite top-line growth. The balance sheet and cash flow present a mixed picture: the company maintains a solid current ratio of 1.68 and a manageable debt-to-equity ratio of 0.94, but its trailing twelve-month free cash flow of $4.32 billion and a negative Return on Equity of -33.44% highlight the disconnect between cash generation and bottom-line profitability, suggesting earnings quality concerns.
Quarterly Revenue
$49.7B
2025-12
Revenue YoY Growth
+0.21%
YoY Comparison
Gross Margin
+0.15%
Latest Quarter
Free Cash Flow
$4.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CNC Overvalued?
Given the negative trailing net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 0.104, which is exceptionally low and reflects the market's deep discount due to recent losses, while the forward PE of 14.63 suggests the market anticipates a return to profitability. Compared to industry averages, specific peer multiples are not provided in the data, but a PS ratio of 0.10 is generally far below typical healthcare plan valuations, indicating the stock is priced for significant fundamental distress or offering deep value if a turnaround materializes. Historically, the current PS ratio of 0.10 is near the bottom of its own range compared to recent quarters where it traded above 0.35, suggesting the stock is at a cyclical low point in valuation, which could represent a value opportunity if the company's earnings stabilize.
PE
-3.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -72x~220x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are centered on a severe profitability crisis, not a lack of revenue. The Q4 2025 net loss of $1.1 billion on $49.7B in revenue, coupled with a gross margin that compressed sequentially to 15.18%, indicates significant underlying cost pressure and medical cost mismanagement. While free cash flow remains positive at $4.32B TTM, the negative ROE of -33.44% shows shareholder capital is being destroyed. The primary risk is that revenue growth fails to translate into profits, making the forward P/E of 14.63—based on an estimated $9.21 EPS—unattainable and triggering a valuation re-rating.
Market & Competitive Risks include valuation compression if the profitability recovery stalls. The stock has rallied 89% in three months, largely on sentiment and technicals, pushing it to test its 52-week high. If upcoming earnings fail to show concrete margin improvement, the stock could swiftly give back gains. Furthermore, as a government-focused managed care organization, CNC is highly sensitive to regulatory changes in Medicaid and Medicare reimbursement rates; while the recent CMS news was positive, future policy shifts could reverse this benefit. Its beta of 1.09 also means it is slightly more volatile than the market, amplifying downside moves in a risk-off environment.
Worst-Case Scenario involves the Q4 2025 loss proving not to be an anomaly but the start of a prolonged period of unprofitability due to persistent medical cost inflation and competitive pricing pressure. This could lead to analyst downgrades, a loss of investor confidence, and a re-test of the 52-week low of $25.08. Given the stock's history of a -59.9% max drawdown, a realistic adverse scenario from the current $65.19 price could see a decline of approximately -61.5% to that low, effectively wiping out the entire recovery rally. The chain of events would be: a Q3 2026 earnings miss on margins, guidance reduction, multiple analyst downgrades to Sell, and a rapid unwind of momentum-driven positioning.